By Rebecca Thurlow SYDNEY--Mayne Pharma Group Ltd. (MYX.AU) said Wednesday it has launched its foam dermatology products Fabior and Sorilux in the...
/newsletter/barneyc/476/mayne-pharma-to-buy-42-drugs
Mayne Pharma Group Limited (“Mayne Pharma”) (ASX: MYX) has acquired a portfolio of dermatology foam products and related assets (“Foam...
By Rebecca Thurlow SYDNEY--Mayne Pharma Group Ltd. (MYX.AU) acquired a portfolio of U.S. generic drugs from Teva Pharmaceutical Industries Ltd...
Australian shares are nearing their highest level since late October on Monday, though falling commodities prices muted gains triggered by...
http://www.fool.com.au/2015/05/07/3-stocks-in-the-buy-zone-and-1-to-avoid/
By Michael Calia Actavis PLC raised its profit guidance for 2015, while acquisitions again helped drive revenue growth in the fourth quarter, as...
Actavis PLC (ACT) will sell the U.S. rights to an acne treatment as it seeks to refine its dermatology portfolio ahead of its purchase of Botox...
By Maria Armental and Robb M. Stewart Actavis PLC (ACT) will sell the U.S. rights to a acne treatment as it seeks to refine its dermatology...
HedgePath Pharmaceuticals Welcomes Three New Board Members Stefan Cross, Dr. Dana Ono and Mark Watson add significant biotechnology, capital...
SYDNEY--Australian pharmaceutical group Mayne Pharma Ltd. is poised to raise around 18 million Australian dollars (US$19 million) to fund the...
NEW YORK, March 20 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) opened trading on Merrill Lynch's 12% Callable STRIDES Linked to...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.